These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 35580655)

  • 1. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
    Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
    Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
    Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
    Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing.
    Selby K; Jensen CD; Levin TR; Lee JK; Schottinger JE; Zhao WK; Corley DA; Doubeni CA
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):145-152. PubMed ID: 33010408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
    Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
    Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
    Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy, Acceptability, and Application: Fecal Immunochemical Tests for Early Detection of Advanced Neoplasia in Colonoscopy-Based Surveillance.
    Wassie MM; Dix M; Laven-Law G; Bulamu N; Cock C; Bampton P; Fraser RJ; Winter JM; Young GP; Symonds EL
    Dig Dis Sci; 2024 Jul; 69(7):2621-2630. PubMed ID: 38753241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study.
    Sadeghi A; Asadzadeh Aghdaei H; Khalafi MA; Nazemalhosseini-Mojarad E; Ketabi Moghadam P; Sohrabi MR
    BMC Cancer; 2023 Jul; 23(1):627. PubMed ID: 37407931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal immunochemical test mitigates risk of delayed colonoscopy in people with elevated risk of colorectal neoplasia.
    Wassie MM; Young GP; Cock C; Bampton P; Winter JM; Simpson K; Saluja H; Chuang A; Fraser RJ; Symonds EL
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1067-1075. PubMed ID: 35261071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How COVID-19 Impacted Colonoscopy Utilization and Colorectal Cancer Detection in Hawai'i in 2020.
    Jain A; Jain S; Pagano I
    Hawaii J Health Soc Welf; 2024 Jul; 83(7):200-203. PubMed ID: 38974803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests.
    Longstreth GF; Anderson DS; Zisook DS; Shi JM; Lin JC
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2929-2936.e1. PubMed ID: 32007541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of Cervical and Colorectal Cancer Screenings During the Pandemic in Community Health Centers: Practice Changes and Recovery Strategies.
    Huguet N; Danna M; Baron A; Hall J; Hodes T; O'Malley J; Holderness H; Marino M; DeVoe JE; Cohen DJ
    Med Care; 2023 Aug; 61(8):554-561. PubMed ID: 37310241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Évaluation de la gravité du cancer colorectal dépisté dans le contexte de la crise sanitaire liée au COVID19 en région Ile-de-France].
    Koïvogui A; Abihsera G; Le Trong T; Ait-Hadad H; Bernoux A; Delattre H; Vincelet C; Caroll R; Nicolet J
    Rev Epidemiol Sante Publique; 2023 Oct; 71(5):102124. PubMed ID: 37451076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.